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Introduction: Leptomeningeal metastasis (LM), or leptomeningeal
carcinomatosis, is a devastating complication of non-small cell lung
cancer (NSCLC), and the optimal therapeutic approach remains
challenging. A retrospective review was carried out to assess the
impact of whole brain radiotherapy (WBRT), intrathecal therapy
(IT), and epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) on outcomes.
Methods: Patients with newly diagnosed LM from NSCLC from
January 2002 to December 2009 were identified through institu-
tional databases and medical records reviewed. Survival was as-
sessed by Kaplan-Meier and landmark analyses by administered
treatment to minimize selection bias.
Results: We identified 125 patients (45 men, 80 women) with LM
from NSCLC, median age 59 years (range, 28–87 years). Almost all
(123 [98%]) patients have died and median overall survival was 3.0
months (95% confidence interval, 2.0–4.0). No differences in sur-
vival were seen between patients who were treated with WBRT (n
46) and those who were not (n  59, p  0.84) in a landmark
analysis. In the seven patients selected to receive IT chemotherapy,
median survival was 18 months (range, 5–33 months) and appeared
superior to those not selected for this treatment (p  0.001) in a
landmark analysis. The median survival of the nine patients with
known EGFR mutations (all of whom received TKIs at some point)
was 14 months (range, 1–28 months).
Conclusions: This retrospective study, the largest published series,
demonstrates the poor survival of LM from NSCLC. In this study,
survival was not improved by WBRT. The survival of patients
selected for IT chemotherapy and those with EGFR mutations
treated with TKIs highlights the importance of developing novel
agents.
Key Words: Non-small cell, Leptomeningeal metastasis, Lepto-
meningeal carcinomatosis, Radiotherapy, Intrathecal chemotherapy.
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In recent years, therapeutic advances have led to improve-ments in survival from non-small cell lung cancer
(NSCLC). Patients with tumors that harbor mutations in the
epidermal growth factor receptor (EGFR) can achieve pro-
longed disease control and survival with tyrosine kinase
inhibitors (TKIs) such as erlotinib and gefitinib.1–5 These
improvements in systemic control and survival may contrib-
ute to a relative increase in the prevalence of leptomeningeal
metastasis (LM) from NSCLC, which remains a devastating
complication associated with poor survival.6,7 The optimal
therapeutic approach for LM remains challenging. Patients
are frequently treated with whole brain radiotherapy
(WBRT), intrathecal therapy (IT) chemotherapy, or rarely
both, but the relative benefits of these approaches remain
poorly characterized. Available literature is based partly on
studies reporting heterogeneous cohorts of patients compris-
ing different solid tumors which vary in terms of chemosen-
sitivity and overall prognosis,8–11 in addition to relatively
small studies specifically reporting on outcomes in LM from
NSCLC.12,13 Thus, overall results may not be applicable to
one type of tumor or different subgroups of patients with
NSCLC. To evaluate treatment patterns and outcomes in
patients with LM from NSCLC, we carried out a retrospec-
tive review of practice at a single institution, with an empha-
sis on the impact of WBRT and IT chemotherapy on out-
comes.
MATERIALS AND METHODS
Patients at Memorial Sloan-Kettering Cancer Center
with newly diagnosed LM from NSCLC between January
2002 and December 2009 were identified through two insti-
tutional databases: a neurology patient database and a pathol-
ogy database of all collected cerebrospinal fluid (CSF) cyto-
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logic specimens. As previously described,7,14 patients were
included in this study if they met one of the following
diagnostic criteria: (1) cytological evidence of malignant cells
on CSF or (2) neuroimaging (gadolinium enhanced T1-
weighted magnetic resonance scan) consistent with LM, as
defined by the presence of multifocal enhancing subarachnoid
nodules. Medical records were reviewed to determine patient
characteristics, patterns of care, and outcomes. Because some
patients with LM have poor performance status, uncontrolled
systemic disease, and resultant limited survival, we per-
formed a landmark analysis to assess the survival impact of
WBRT and IT chemotherapy. This methodology was used in
an attempt to remove selection bias because patients are only
included if they survive a predetermined time from LM
diagnosis. In this analysis, patients were included after diag-
nosis of LM if they survived 30 days (WBRT) and 45 days
(IT chemotherapy). In addition, those who did survive were
included as WBRT treated only if they had received WBRT
by 30 days after LM diagnosis. Similarly for IT chemother-
apy, patients had to have received IT chemotherapy by 45
days after LM diagnosis and also have been followed for 45
days or more. These two time points were chosen as from our
dataset it was clear that radiation was given within 30 days of
diagnosis, whereas a course of IT chemotherapy was admin-
istered over 45 days. Hence, different time points were
chosen to minimize the different selection bias associated
with the different approaches. The Kaplan-Meier method was
used to examine survival from date of LM diagnosis to date
of death or date of last follow-up. Survival comparisons were
made using the log-rank test statistic.
RESULTS
We identified 125 patients (45 men, 80 women) who
met the inclusion criteria with LM from NSCLC, median age
59 years (range, 28–87 years) and median Karnofsky Per-
formance Status 70 (range, 30–100). The median time from
initial NSCLC diagnosis to LM was 15 months (range, 0–121
months). Parenchymal brain metastases (prior or current)
were noted in 102 (82%) patients, of whom 54 (53%) had
received prior WBRT. In total, 42 (34%) patients had symp-
toms or signs of raised intracranial pressure, of whom 16
(38%) underwent ventriculoperitoneal shunt. Almost all (123
[98%]) patients are known to have died and one was lost to
follow-up. The median overall survival was 3.0 months (95%
confidence interval, 2.0–4.0 months) and the overall survival
is shown in Figure 1. Most patients (97 [78%]) had adenocar-
cinomas and the other histological subtypes were as follows;
squamous—4, NSCLC with neuroendocrine features—3, bron-
choalveolar—2, large cell—2, adenosquamous—1, and NSCLC
not otherwise specified—16. Of the 97 patients with adenocar-
cinoma, 61 (63%) were women and 36 (37%) were men. This
gender distribution was similar in the 28 patients with other
histologies (68% women, 32% men), p  0.63. The improved
survival of patients with adenocarcinoma (n  97) compared
with patients with other histologies (n 28) (p 0.04) is shown
in Figure 2.
The initial therapies administered for LM are shown in
Table 1. WBRT was administered using a linear accelerator
FIGURE 1. Overall survival from diagnosis of leptomenin-
geal metastasis.
FIGURE 2. Overall survival by histological subtype.
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and 6 MV photons, with doses ranging from 3000 to 3750
cGy, delivered in 10 to 15 fractions. After LM diagnosis, 56
(45%) patients were treated with WBRT, of whom 46 re-
ceived WBRT by 30 days after LM diagnosis and survived
30 days after LM diagnosis. These patients were included
in the landmark analysis and compared with the 59 patients
who had not received WBRT by 30 days after LM diagnosis
and who survived 30 days. As shown in Figure 3, no
differences in survival were seen between patients who were
treated with WBRT and those who were not (p  0.84).
In total, seven (6%) patients, none of whose tumors
were known to have a mutation in EGFR (six untested, one
no mutation) received IT chemotherapy. The IT chemother-
apy consisted of biweekly methotrexate (n  5, median of 9
doses received) or liposomal cytarabine (n  2, median of 6
doses). The median survival in the seven patients selected for
IT chemotherapy was 18 months (range, 5–33 months). Of
these, six received IT chemotherapy by 45 days after LM
diagnosis and survived 45 days and were compared in the
landmark analysis to the 83 patients who did not receive IT
chemotherapy by 45 days after LM diagnosis and who sur-
vived 45 days. Although the overall numbers were small, it
appeared that patients who were selected for IT chemother-
apy survived longer than those who were not (p  0.001)
(Figure 4).
Tissue analyses from nine (7%) patients (five women,
four men), all of whom had adenocarcinomas, were found to
harbor mutations in EGFR. In 20 (16%) patients, there was no
evidence of EGFR mutations and the status of the remaining
96 (77%) was unknown because this study was largely
conducted before widespread testing for EGFR mutations.
The nine patients with EGFR mutations developed LM at a
median of 19 months (range, 2–47 months) from primary
NSCLC diagnosis. In four (44%) of these patients, therapy
with EGFR TKIs was ongoing in the month preceding LM
diagnosis, two of these received WBRT and two had a change
in systemic therapy as initial therapy for LM, but all four had
subsequent EGFR TKI therapy. In addition, four (44%) other
patients received EGFR TKIs subsequent to LM diagnosis.
Hence, eight (89%) of nine patients with known EGFR
mutations received EGFR TKIs at some time subsequent to
the diagnosis of LM. The final patient had discontinued
erlotinib 6 months before LM due to toxicity. The median
survival of the nine patients with known EGFR mutations
was 14 months (range, 1–28 months).
DISCUSSION
To the best of our knowledge, this retrospective study
of 125 patients represents the largest published series on LM
from NSCLC. This devastating clinical problem was associ-
ated with an extremely poor prognosis, with a median sur-
vival of only 3.0 months. Furthermore, using a landmark
analysis, survival was poor whether or not patients were
selected for WBRT, and therefore, we question the routine
use of this approach in clinical practice. Although WBRT
may play a role in symptom control, there is a lack of
evidence supporting a survival benefit from available stud-
ies.13,15 For example, in a retrospective study by Chuang et
al.,12 median overall survival was similarly short in patients
who received WBRT (median, 5.6 weeks, n  16) and those
who did not (median, 2.9 weeks, n  18), p  0.2. The
retrospective nature of our study prevents assessment of
whether WBRT improved neurologic symptoms or quality of
life, or whether it was associated with any toxicities.
In this report, 80 (64%) were women but no association
was seen between gender and histological subtype, and the
clinical importance of this finding is unclear. We also found
a high incidence of raised intracranial pressure, which was
diagnosed in 34% of our patients. Recognizing this compli-
cation is important because some patients with LM benefit
from a ventriculoperitoneal shunt for palliation of symptoms,
and shunt placement precludes the delivery of chemotherapy
through an Ommaya reservoir. Thus, a lumbar puncture with
CSF pressure measurement should be considered in patients
FIGURE 3. Overall survival by whole brain radiotherapy
(WBRT). Proportion of patients surviving from date of lepto-
meningeal metastasis, by receipt of WBRT, landmarked at 30
days.
FIGURE 4. Overall survival by intrathecal (IT) chemotherapy.
Proportion of patients surviving from date of leptomeningeal
metastasis, by receipt of intrathecal chemotherapy, land-
marked at 45 days.
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presenting with headache, nausea, and vomiting.16 It must
also be noted that raised intracranial pressure can occur in the
absence of ventricular dilatation, and a ventriculoperitoneal
shunt in this setting may also be helpful.16
The role of IT chemotherapy in solid tumors remains to
be established. In our series, landmark analysis showed that
patients selected to receive IT chemotherapy achieved pro-
longed survival (median, 18 months) compared with those
who were not selected to receive this therapy (p  0.001,
Figure 4). Although definitive conclusions are limited by the
small number of patients and the selection bias, this finding
suggests that medical therapy with IT therapy or agents,
which adequately penetrate the CSF, may play an important
role in central nervous system disease control in some pa-
tients and be an important avenue of future research for the
treatment of LM from NSCLC. This was seen even though
agents traditionally used through the IT route such as meth-
otrexate and cytarabine have limited activity in NSCLC. The
impact of systemic chemotherapy on LM remains unclear,
but anecdotal experience suggests that responses in LM may
be attainable with agents active against NSCLC.
Many of the patients in this study represent a historic
cohort, before the widespread testing for EGFR mutations
and the use of EGFR TKIs. Nevertheless, in the small sample
(n  9) of patients with known sensitizing mutations in
EGFR, a relatively long median survival of 14 months was
seen. Because of the large number of patients with unknown
EGFR mutation status (77%) and variable clinical practice
relative to the introduction of EGFR TKIs, we were unable to
elucidate the prognostic and predictive significance of sensi-
tizing mutations in our population; however, the data suggest
that this group of patients has superior survival to the overall
cohort (median, 3.0 months). These findings are consistent
with case reports and other series, which have demonstrated
durable clinical benefit from TKIs such as erlotinib for
patients with LM and sensitive EGFR mutations.17–20 Fur-
thermore, high-dose weekly erlotinib has been proposed as a
possible therapeutic strategy for these patients, because this
may increase CSF penetration.21 These and other approaches
may be appropriate for some patients and may offer improve-
ment in outcomes for subgroups of patients with EGFR
mutations. However, in the absence of EGFR mutations,
alternative strategies are needed urgently. In that setting, the
monoclonal antibody bevacizumab has shown some activity,
but further validation of this approach and additional studies
of active agents with adequate central nervous system pene-
tration are needed.22
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